The 340B Drug Pricing Program is one of those parts of the U.S. healthcare system that most people have never heard of and that nonetheless quietly affects the medications a meaningful share of patients receive. Created by Congress in 1992 and administered by the Health Resources and Services Administration, the programme requires drug manufacturers participating in Medicaid to provide outpatient drugs at significantly reduced prices to qualifying healthcare organisations.
The qualifying organisations include federally qualified health centres, Ryan White HIV/AIDS programme grantees, certain children’s hospitals, certain critical access hospitals, disproportionate share hospitals serving a high share of low-income patients, and several other categories defined in statute. The intent of the programme, in its original Congressional framing, was to allow safety-net providers to stretch limited federal resources further by reducing what they pay for outpatient medications.
For specialty pharmaceuticals — biologics, plasma-derived therapies, oncology agents, immunology medications — the 340B price differential is meaningful. Specialty drugs frequently cost tens or hundreds of thousands of dollars per patient per year, and the 340B discount creates a margin that safety-net institutions can use to fund care that would not otherwise be financially sustainable.
How a 340B specialty pharmacy actually operates
A 340B Specialty Pharmacy is a specialty pharmacy that contracts with one or more 340B-eligible covered entities to dispense medications under 340B pricing for eligible patients of those entities.
The model is operationally complex. The pharmacy must verify patient eligibility under the contract pharmacy rules, maintain inventory separation or virtual inventory management to track 340B-purchased drugs separately from non-340B inventory, comply with HRSA audit requirements, and avoid duplicate discounts where Medicaid rebates would also apply.
The compliance burden is real. HRSA audits, manufacturer audits, and self-audits are all part of the operating environment, and the documentation requirements are substantial. Specialty pharmacies operating in this space typically maintain dedicated 340B compliance teams alongside their clinical and dispensing operations.
The Health Affairs journal and various peer-reviewed health policy publications have documented both the benefits and the controversies of the programme over its three decades, with debate continuing about scope, qualifying entity definitions, contract pharmacy arrangements, and manufacturer obligations.
What it changes for patients
For eligible patients receiving care from 340B-qualifying institutions, the programme expands access to specialty therapies that the institution might not otherwise be able to provide. The patient does not see the pricing mechanics; they see expanded availability of medications that would otherwise be financially out of reach for the institution to support.
For the broader system, the programme funds a meaningful portion of the safety-net pharmacy infrastructure in the United States, particularly in rural areas and inner-city federally qualified health centres where conventional pharmacy economics do not support specialty drug provision.
See also: How Everyday Moments Can Impact Our Future Health
FAQ
Who qualifies as a 340B-eligible entity? Federally qualified health centres, Ryan White grantees, certain children’s hospitals, critical access hospitals, disproportionate share hospitals, and several other categories defined in the statute.
Is the patient billed differently under 340B? Patient billing is largely unaffected by 340B. The pricing differential is between the pharmacy and the manufacturer; insurance billing and patient cost-sharing follow the patient’s coverage.
Why is 340B controversial? Debate centres on the scope of the programme, the contract pharmacy arrangements that have grown around it, manufacturer obligations, and the use of 340B revenue by qualifying entities.
